Ling Jin

Dr. Ling Jin

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XCXiao Cui
Xiao Cui
LYLei Ye
Lei Ye
JLJing Li
Jing Li
LJLing Jin
Ling Jin
WWWenjie Wang
Wenjie Wang
JCJun Cai
Jun Cai
Previous studies suggested a possible gut microbiota dysbiosis in chronic heart failure (CHF). However, direct evidence was lacking. In this study, we investigated the composition and metabolic patterns of gut microbiota in CHF patients to provide direct evidence and comprehensive understanding of gut microbiota dysbiosis in CHF. We enrolled 53 CHF patients and 41 controls. Metagenomic analyses of faecal samples and metabolomic analyses of faecal and plasma samples were then performed. We found that the composition of gut microbiota in CHF was significantly different from controls. Faecalibacterium prausnitzii decrease and Ruminococcus gnavus increase were the essential characteristics in CHF patients’ gut microbiota. We also observed an imbalance of gut microbes involved in the metabolism of protective metabolites such as butyrate and harmful metabolites such as trimethylamine N-oxide in CHF patients. Metabolic features of both faecal and plasma samples from CHF patients also significantly changed. Moreover, alterations in faecal and plasma metabolic patterns correlated with gut microbiota dysbiosis in CHF. Taken together, we found that CHF was associated with distinct gut microbiota dysbiosis and pinpointed the specific core bacteria imbalance in CHF, along with correlations between changes in certain metabolites and gut microbes.

1 February 2018 in Hypertension
Verified
Journal Article
Closed access
PDF file
LJLing Jin
Ling Jin
XLXianjuan Lin
Xianjuan Lin
LYLei Yang
Lei Yang
XFXiaofang Fan
Xiaofang Fan
WWWenjie Wang
Wenjie Wang
JCJun Cai
Jun Cai
Recent studies reported some long noncoding RNAs (lncRNAs)–mediated vascular smooth muscle cells (VSMCs) phenotypic switch, which was a common pathophysiological process of vascular diseases. However, whether human-specific expressed lncRNAs would modulate VSMCs phenotype and participate into the pathogenesis of essential hypertension remains unclear. By comparing the circulating lncRNAs expression profiles between hypertensive patients and healthy controls, we identified a lncRNA-AK098656, strongly upregulated in the plasma of hypertensive patients, and predominantly expressed in VSMCs. AK098656 promoted VSMCs synthetic phenotype evidenced by increasing VSMC proliferation and migration, elevating extracellular matrix proteins, whereas lowering contractile proteins. Furthermore, AK098656 was demonstrated to directly bind with the VSMCs-specific contractile protein, myosin heavy chain-11, and an essential component of extracellular matrix, fibronectin-1, and finally lowered these protein levels through protein degradation. AK098656 was also shown to bind with 26S proteasome non-ATPase regulatory subunit 11 and facilitated myosin heavy chain-11 to interact with this protein. In vivo, AK098656 transgenic rats showed spontaneous development of hypertension, with elevated VSMCs synthetic phenotype and narrowed resistant arteries. Transgenic rats also showed slight cardiac hypertrophy without other complications, which was similar with early pathophysiological changes of hypertension. All these data indicated AK098656 as a new human VSMC-dominant lncRNA, which could promote hypertension through accelerating contractile protein degradation, increasing VSMC synthetic phenotype, and finally narrowed resistance arteries.

23 May 2017 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
NWNa Wu
Na Wu
LJLing Jin
Ling Jin
JCJun Cai
Jun Cai
Objectives: CircRNAs, a novel class of noncoding RNAs, have been reported in many diseases. However, their role in hypertension remains unclear. Here, we aimed to determine the circRNA expression profile in hypertension patients and further construct a circRNA–miRNA–mRNA network for mechanism exploration. Methods: Plasma circRNA expression profiles were screened by circRNA microarrays and verified by qRT-PCR method. CircRNA–miRNA–mRNA network was established to predict the circRNA targets. Gene ontology (GO) analysis and KEGG pathway analysis were applied for further enrichment of mRNA data. Results: CircRNA microarrays study identified 13 downregulated and 46 upregulated circRNAs in hypertension patients, where four circRNAs (hsa-circ-0000437, hsa-circ-0008139, hsa-circ-0005870 and hsa-circ-0040809) showed significantly difference. By further validation, hsa-circ-0005870 exhibited significant downregulation in hypertensive patients. Then, we constructed a network of hsa-circ-0005870-targeted miRNAs, including hsa-miR-6807-3p, hsa-miR-5095, hsa-miR-1273g-3p, hsa-miR-5096, hsa-miR-619-5p, and their corresponding mRNAs. Gene oncology and KEGG pathway analysis enriched from specific mRNAs indicated the involvement of hsa-circ-0005870 in hypertension. Conclusions: In summary, hsa-circ-0005870 may represent a novel biomarker for the diagnosis of hypertension, and hsa-circ-0005870-miRNA-mRNA network may provide potential mechanism for hypertension.

1 July 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
LJLing Jin
Ling Jin
QSQirui Song
Qirui Song
WZWeili Zhang
Weili Zhang
BGBin Geng
Bin Geng
JCJun Cai
Jun Cai

31 May 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
LJLing Jin
Ling Jin
JTJian Tu
Jian Tu
JJJianwei Jia
Jianwei Jia
WAWenbin An
Wenbin An
HTHuanran Tan
Huanran Tan
ZLZhixin Li
Zhixin Li
Drug-induced gene expression dataset (for example Connectivity Map, CMap) represent a valuable resource for drug-repurposing, a class of methods for identifying novel indications for approved drugs. Recently, CMap-based methods have successfully applied to identifying drugs for a number of diseases. However, currently few gene expression based methods are available for the repurposing of combined drugs. Increasing evidence has shown that the combination of drugs may valid for novel indications. Here, for this purpose, we presented a simple CMap-based scoring system to predict novel indications for the combination of two drugs. We then confirmed the effectiveness of the predicted drug combination in an animal model of type 2 diabetes. We applied the presented scoring system to type 2 diabetes and identified a candidate combination of two drugs, Trolox C and Cytisine. Finally, we confirmed that the predicted combined drugs are effective for the treatment of type 2 diabetes. The presented scoring system represents one novel method for drug repurposing, which would provide helps for greatly extended the space of drugs.

22 January 2014 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
HLHui Li
Hui Li
XWXi Wang
Xi Wang
YMYiqing Mao
Yiqing Mao
RHRuobi Hu
Ruobi Hu
WXWei Xu
Wei Xu
HTHuanran Tan
Huanran Tan
The liver-specific glucokinase knockout (gckw/–) mouse experiences long-term hyperglycemia and insulin resistance. This study was designed to evaluate the functional and structural changes in the myocardium of 60 week-old gckw/– mice, and to investigate the effect of rosiglitazone on the myocardium in this model. 60 week-old gckw/– mice were randomly divided into 3 groups: gckw/–, gckw/– mice treated with insulin (1 U/kg) and gckw/– mice treated with rosiglitazone (18 mg/kg). Insulin or rosiglitazone treatment was for 4 weeks. Gckw/w litermates were used as controls. Echocardiography, electrocardiogram, biochemical, histopathological, ultrastructural, real time PCR and Western blot studies were performed to examine for structural and functional changes. Long-term liver-specific gck knockout in mice elicits hyperglycaemia and insulin resistance. Compared to age matched gckw/w mice, 60 week-old gckw/– mice showed decreased LV internal dimension, increased posterior wall thickness, lengthened PR and QRS intervals, up-regulated MLC2 protein expression, decreased SOD activity, increased MDA levels and up-regulated Cyba mRNA. Morphological studies revealed that there was an increase in the amount of PAS and Masson positively stained material, as did the number and proportion of the cell occupied by mitochondria in the gckw/– mice. Western blot analysis revealed that the levels of the insulin receptor, Akt, phosphorylated AMPK beta and phosphorylated ACC were reduced in gckw/– mice. These effects were partly attenuated or ablated by treatment with rosiglitazone. Our results indicate that changes in the myocardium occur in the liver-specific glucokinase knockout mouse and suggest that reduced glucokinase expression in the liver may induce diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK protein levels. Rosiglitazone treatment may protect against diabetic cardiomyopathy by altering the levels of a set of proteins involved in cardiac damage.